Cytogenetically defined subgroups of AML can be further refined and subclassified with NGS analysis: In 2016 Duployez et al. performed sequencing with a 40 gene panel in 215 patients with CBF AML (i.e., AML with t(8;21) or inv(16)) [39]. This evidence concerns the gene CEBPZ and acute myeloid leukemia.